Using a closure analysis method to reduce CGT contamination risks
Many cell therapy manufacturing processes use open unit manipulations. As a result, they are at risk of potential contam...
Addressing the challenges of using RNA as a therapeutic or a gene-editing tool
RNA technologies, including mRNA therapeutics, have emerged as a promising drug modality due to their essential biological role in protein expression and their potential versatility in manufacturing. As a result, RNA is ...
Using a closure analysis method to reduce CGT contamination risks
Many cell therapy manufacturing processes use open unit manipulations. As a result, they are at risk of potential contam...
Bridging the worlds of IT and CGT through analogies
Cell and gene therapies (CGTs) have enormous potential to create personalized therapeutics for patients with diseases...
BioPhorum’s Deliverables Report 2021 – all of our content at your fingertips
Where can you read about industry trends, progress against shared challenges, and best practice solutions...
A simplified way to register complex and innovative raw materials in Europe
The regulatory environment for registering innovative and complex raw materials differs by region and country. All natio...
Using a matrix approach to address challenges for potency assay development for in vivo and ex vivo gene therapies.
The gene therapy field is advancing rapidly and though there has been significant progress, there are yet relatively few...
RNA: new CGT workstream to focus on this industry priority
When planning the 2021 BioPhorum Cell & Gene Therapy program, senior member representatives indicated that they want...
Assessing EHS risks in CGT: a real-world example
In 2020, the Cell and Gene Therapy Phorum published an article Environmental Health and Biosafety Risk Assessment Guidan...
Illuminating the challenges of validating cell and gene therapies
The validation processes for general biologics and small molecule drugs are well established and there are many guidelin...
Release specifications for master cell banks – your chance to make a difference
Gene therapy (GT) is a rapidly expanding field that could potentially revolutionize curative treatments and is an exciti...
BioPhorum launch new sustainability phorum
BioPhorum members have given us a clear message; to be an industry that supports sustainability is extremely important t...
Chain reaction: how the biopharmaceutical supply chain survived the pandemic
LONG READChain reaction: how the biopharmaceutical supply chain survived the pandemicThe pressure on the...
Overcoming unique challenges to support rapid development of diverse products
LONG READOvercoming unique challenges to support rapid development of diverse productsThe Cell and Gene Therapy (CGT)...
Addressing the challenges of using RNA as a therapeutic or a gene-editing tool
RNA technologies, including mRNA therapeutics, have emerged as a promising drug modality due to their essential biologic...
Using a closure analysis method to reduce CGT contamination risks
Many cell therapy manufacturing processes use open unit manipulations. As a result, they are at risk of potential contam...
Bridging the worlds of IT and CGT through analogies
Cell and gene therapies (CGTs) have enormous potential to create personalized therapeutics for patients with diseases...
BioPhorum’s Deliverables Report 2021 – all of our content at your fingertips
Where can you read about industry trends, progress against shared challenges, and best practice solutions...
A simplified way to register complex and innovative raw materials in Europe
The regulatory environment for registering innovative and complex raw materials differs by region and country. All natio...
Using a matrix approach to address challenges for potency assay development for in vivo and ex vivo gene therapies.
The gene therapy field is advancing rapidly and though there has been significant progress, there are yet relatively few...
RNA: new CGT workstream to focus on this industry priority
When planning the 2021 BioPhorum Cell & Gene Therapy program, senior member representatives indicated that they want...
Assessing EHS risks in CGT: a real-world example
In 2020, the Cell and Gene Therapy Phorum published an article Environmental Health and Biosafety Risk Assessment Guidan...
Illuminating the challenges of validating cell and gene therapies
The validation processes for general biologics and small molecule drugs are well established and there are many guidelin...
Release specifications for master cell banks – your chance to make a difference
Gene therapy (GT) is a rapidly expanding field that could potentially revolutionize curative treatments and is an exciti...
BioPhorum launch new sustainability phorum
BioPhorum members have given us a clear message; to be an industry that supports sustainability is extremely important t...
Chain reaction: how the biopharmaceutical supply chain survived the pandemic
LONG READChain reaction: how the biopharmaceutical supply chain survived the pandemicThe pressure on the...